KalVista Pharmaceuticals (NASDAQ:KALV) has announced that Jeb Ledell has been appointed as chief operating officer (COO). Mr. Ledell brings more than 20 years of leadership and operational excellence in the...
SVB Leerink initiated coverage of Kalvista Pharmaceuticals (NASDAQ:KALV) with an “outperform” rating and $31 price target. The stock closed at $16.92 on July 26. Kalvista is creating a new generation of small molecule...